Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Krankenhaus Nordwest GmbH

Research site

Germany Steinbacher Hohl 2-26, Praunheim, 60488 Frankfurt, Germany

  • 65 trials recruiting
  • Non-small cell lung cancer · Oesophageal adenocarcinoma · Colorectal cancer metastatic
  • Adults and children

About Specializations

Krankenhaus Nordwest GmbH in Frankfurt, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Oesophageal adenocarcinoma, Colorectal cancer metastatic, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Non-Small Cell Lung Cancer (NSCLC)

The medical center is at the forefront of research in Non-Small Cell Lung Cancer (NSCLC), focusing on innovative therapies that target specific genetic markers and immune checkpoints. The center's trials explore the efficacy of novel combinations of immunotherapies and targeted treatments to improve patient outcomes.

  • Anti-TIGIT and Anti-PD-L1 Antibodies
  • ALK+ NSCLC Treatments
  • KRAS G12C Mutation Therapies

These studies aim to enhance progression-free survival and overall survival rates, offering new hope for patients with advanced stages of the disease.

Small Cell Lung Cancer (SCLC)

Research at the center includes cutting-edge trials for Small Cell Lung Cancer (SCLC), focusing on combination therapies that integrate radiochemotherapy with novel immunotherapeutic agents. These studies aim to improve the progression-free survival rate and overall survival in patients with extensive-stage SCLC.

  • Durvalumab and Radiotherapy Combinations
  • Innovative Chemotherapy Regimens

The center's work in this area is pivotal in developing more effective treatment protocols for this aggressive cancer type.

Gastrointestinal Cancers

The center is a leader in the study of Gastrointestinal Cancers, including gastric, gastroesophageal, and biliary tract cancers. Research efforts focus on the integration of immunotherapy with standard chemotherapy to enhance treatment efficacy and patient survival.

  • HER2-Positive Gastric Cancer Therapies
  • FGFR2b-Positive Adenocarcinoma Treatments
  • Combination Immunotherapy Approaches

These trials are crucial in advancing therapeutic options and improving quality of life for patients with these challenging malignancies.

Colorectal Cancer

In the realm of Colorectal Cancer, the center is pioneering research into the use of immunotherapy and targeted treatments to improve disease-free survival and overall survival rates. The focus is on patients with advanced stages and specific genetic profiles, such as MSI-high or MMR-deficient tumors.

  • Adjuvant Immunotherapy Trials
  • Combination Chemotherapy Studies

These efforts are aimed at providing more personalized and effective treatment strategies for colorectal cancer patients.

Hepatocellular Carcinoma

The center's research in Hepatocellular Carcinoma focuses on innovative treatment combinations that include immunotherapy and targeted agents. These studies are designed to improve response rates and survival outcomes for patients with advanced liver cancer.

  • Combination Immunotherapy Trials
  • Targeted Therapy Approaches

By exploring these novel therapeutic avenues, the center aims to set new standards in the management of hepatocellular carcinoma.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Steinbacher Hohl 2-26, Praunheim60488 FrankfurtGermany
Open in maps ↗
Recruiting now
65 trials
Conditions studied
68

More sites in FrankfurtGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

142 clinical trials

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Colorectal cancer metastatic

Recruiting

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Gastrointestinal carcinoma

Recruiting

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Oesophageal squamous cell carcinoma

Recruiting

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Acute myocardial infarction

Recruiting

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Medical University Of Graz

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Gastrooesophageal cancer+6

Recruiting

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.